A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus
Latest Information Update: 24 Dec 2021
At a glance
- Drugs Anifrolumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors MedImmune
- 22 Nov 2020 Results assessing long-term safety and tolerability of anifrolumab in patients with moderate to severe systemic lupus erythematosus, published in the Arthritis and Rheumatology.
- 17 Aug 2018 Status changed from active, no longer recruiting to completed.
- 04 Oct 2017 Planned End Date changed from 20 Jul 2018 to 1 Aug 2018.